SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vip who wrote (134)6/13/1997 12:35:00 PM
From: Biomaven   of 670
 
Vip: When I said "ex-insider" I was speaking from an investment viewpoint rather than technically. Obviously as Chairman he is still an insider for all reporting purposes, and is also subject to Rule 144 resale requirements - which means he couldn't just dump all his shares on the open market at once.

There are reported to be 200,000 hair transplant procedures a year. If Graftcyte works as advertized I think they will get very good penetration very quickly. Anyone who is vain enough to go throught the unpleasantness of a hair transplant will certainly be prepared to spend the money to speed up the subsequent regrowth. Also the transplant doctors are very interested in their patients being pleased , as they perform multiple procedures on the same patients.

I'm not quite sure about what their Graftcyte pricing is going to be, as the packs themselves are not being sold to the public. Their "hydrating mist" product is being sold to the general public, at $20/per bottle. A posting in alt.baldspot says that the package insert says they are also going to come out with a shampoo, conditioner and gel. The poster says that you'd need a bottle a week.
"but what's an extra $60 if you just spent $10k on a transplant."

Procyte currently has minimal sales, and this makes it much harder to attract larger companies. My best-case scenario is that sales of Graftcyte pick up rapidly, and this will provide a "proof of concept" to encourage a bigger firm to buy Procyte or to fund Phase III Tricomin trials. Procyte would get a much better deal if they have a successful product under their belt.

I'm skeptical that Procyte by itself will be able to successfully market generalised wound-care products, but I think they will be able to market to the much narrower hair transplant market.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News